Simon Tual-Chalot
Overview
Explore the profile of Simon Tual-Chalot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mavraganis G, Georgiopoulos G, Zervas G, Aivalioti E, Delialis D, Petropoulos I, et al.
Eur J Clin Invest
. 2025 Feb;
:e70006.
PMID: 39989380
Background: Recent evidence suggests that Alzheimer's amyloid-beta (1-40) (Αβ1-40), an emerging biomarker of cardiovascular disease, may be involved in the heart-brain-renal axis. We aimed to comprehensively explore the association between...
2.
Liberale L, Tual-Chalot S, Sedej S, Ministrini S, Georgiopoulos G, Grunewald M, et al.
Nat Rev Cardiol
. 2025 Feb;
PMID: 39972009
Ageing of the cardiovascular system is associated with frailty and various life-threatening diseases. As global populations grow older, age-related conditions increasingly determine healthspan and lifespan. The circulatory system not only...
3.
Aivalioti E, Georgiopoulos G, Tual-Chalot S, Bampatsias D, Delialis D, Sopova K, et al.
Eur Heart J
. 2024 Nov;
46(3):250-272.
PMID: 39527015
Epidemiological evidence suggests the presence of common risk factors for the development and prognosis of both cardio- and cerebrovascular diseases, including stroke, Alzheimer's disease, vascular dementia, heart, and peripheral vascular...
4.
Georgiopoulos G, Athanasopoulos S, Mavraganis G, Konstantaki C, Papaioannou M, Delialis D, et al.
J Clin Endocrinol Metab
. 2024 Sep;
PMID: 39257198
Aims: Non-alcoholic fatty liver disease (NAFLD) with advanced liver fibrosis is associated with cardiovascular disease (CVD). To examine if markers of vascular injury mediate the link between liver fibrosis non-invasive...
5.
Camacho-Encina M, Booth L, Redgrave R, Honkanen-Scott M, Scott 3rd W, Martin-Ruiz C, et al.
Cardiovasc Res
. 2024 Sep;
120(17):2163-2165.
PMID: 39238367
No abstract available.
6.
Delialis D, Georgiopoulos G, Tual-Chalot S, Angelidakis L, Aivalioti E, Mavraganis G, et al.
Sci Rep
. 2024 Jun;
14(1):14944.
PMID: 38942831
Circulating amyloid-beta 1-40 (Αb40) has pro-atherogenic properties and could serve as a biomarker in atherosclerotic cardiovascular disease (ASCVD). However, the association of Ab40 levels with morphological characteristics reflecting atherosclerotic plaque...
7.
Amponsah-Offeh M, Tual-Chalot S, Stellos K
Eur Heart J
. 2024 Apr;
45(18):1681-1683.
PMID: 38666350
No abstract available.
8.
Tual-Chalot S, Stellos K
Cardiovasc Res
. 2024 Mar;
120(4):e5-e8.
PMID: 38554379
No abstract available.
9.
Rios F, De Ciuceis C, Georgiopoulos G, Lazaridis A, Nosalski R, Pavlidis G, et al.
Hypertension
. 2024 Mar;
81(6):1218-1232.
PMID: 38511317
Inflammatory responses in small vessels play an important role in the development of cardiovascular diseases, including hypertension, stroke, and small vessel disease. This involves various complex molecular processes including oxidative...
10.
Redgrave R, Singh E, Tual-Chalot S, Park C, Hall D, Bennaceur K, et al.
Am J Pathol
. 2023 Oct;
194(4):562-573.
PMID: 37832870
Coronary reperfusion after acute ST-elevation myocardial infarction (STEMI) is standard therapy to salvage ischemic heart muscle. However, subsequent inflammatory responses within the infarct lead to further loss of viable myocardium....